Clinical trials: Pulmonary Tuberculosis (TB)
Tuberculosis, Tuberculosis, Pulmonary
Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
- Trial name
- NCT04865536
- Testing
- TBI-223 1800 mg, TBI-223 2400mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Post Tuberculosis
Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease
Tuberculosis (TB) affects millions of people worldwide, and many individuals continue to experience long-term health problems even after completing TB treatment.
- Trial name
- AFTER-TB (NCT07731009)
- Testing
- Pulmonary rehabilitation
- Volunteers
- 760 people
- Sponsor
- Jose Antonio Dominguez Benitez
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Respiratory Tract Infections, Tuberculosis, Pulmonary
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
This is an observational cohort study. Pulmonary tuberculosis (TB) patients will be enrolled at the time of TB diagnosis and prospectively followed for at least two years after TB-treatment initiation with optional prolonged…
- Trial name
- TBSEQUEL (NCT03251196)
- Testing
- No Intervention, and Observational Study
- Where
- 4 sites in Mozambique, South Africa and 2 more
- Volunteers
- 1,500 people
- Sponsor
- The Aurum Institute NPC
Pulmonary Tuberculosis
Using Biomarkers to Predict TB Treatment Duration
Background: Tuberculosis (TB) is a bacterial lung infection. Typical treatment using anti-TB drugs lasts about 6 months. Some people with less severe TB might not need to take the drugs that long.
- Trial name
- NCT02821832
- Testing
- Saliva collection, Urine collection, Sputum collection
- Where
- South Africa
- Volunteers
- 946 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary
VDOT and Mobile Payments in Cambodia
This project proposes to develop and pilot a novel smart phone-based intervention to improve tuberculosis (TB) treatment adherence in Cambodia, which integrates video-enabled Directly Observed Treatment (vDOT) with an automated…
- Trial name
- NCT03547479
- Testing
- VDOT, VDOT + mobile money
- Sponsor
- University of Southern California
Pulmonary Tuberculosis
Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)
Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated macrophages and induces expression and release of the cathelicidin, LL-37, a human antimicrobial peptide involved in killing of MTB.
- Trial name
- NCT01580007
- Testing
- Active Sodium Phenylbutyrate and active cholecalciferol
- Where
- Bangladesh
- Volunteers
- 288 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Multi-drug Resistant Tuberculosis
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Deltyba Registry aims to collect the usage information of Deltyba which could be a factor of developing resistance in actual clinical settings.
- Trial name
- NCT03470233
- Where
- 2 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Pulmonary Tuberculosis
Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB
Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB) Introduction: Tuberculosis (TB) places severe pressure on health care services of the developing world.
- Trial name
- ScreenTB (NCT03350048)
- Testing
- Trans-Dot point-of-care test
- Where
- 10 sites in Ethiopia, Germany and 6 more
- Volunteers
- 969 people
- Sponsor
- Prof Gerhard Walzl
Tuberculosis, Pulmonary
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates.
- Trial name
- ESCAPE-TB (NCT04856644)
- Testing
- 4-month rifapentine-based regimen
- Where
- 4 sites in Taiwan
- Volunteers
- 333 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Tuberculosis, Tuberculosis, Pulmonary
Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa
The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine LAM test in detecting tuberculosis in HIV-infected adults.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Miliary
- Trial name
- NCT01693224
- Testing
- Alere "Determine" lateral-flow urine lipoarabinomannan assay, Alere "Clearview" ELISA urine LAM assay, Cepheid Xpert MTB/Rif assay
- Where
- 2 sites in South Africa
- Volunteers
- 512 people
- Sponsor
- Tuberculosis Clinical Diagnostics Research Consortium
Pulmonary Tuberculosis
Improving Community Based Tuberculosis Care in Ethiopia
The purpose of this study is to see if involving community health workers improves tuberculosis case finding and treatment outcome.
- Trial name
- community (NCT00803322)
- Where
- Ethiopia
- Volunteers
- 318 people
- Sponsor
- University of Bergen
Tuberculosis
The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis
The investigators will evaluate the usefulness of QuantiFERON-TB Gold in-tube (QFT) in the diagnosis of active tuberculosis in young adults group, highly clinically suspected tuberculosis.
- Trial name
- NCT00982969
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Armed Forces Capital Hospital, Republic of Korea
Pulmonary TB
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
- Trial name
- NCT03678688
- Testing
- 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832
- Where
- 3 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
PRACTECAL-PKPD Sub Study
PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the TB-PRACTECAL trial investigational regimens and…
- Conditions
- Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculosis
- Trial name
- PRACTECAL-PKPD (NCT04081077)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 5 sites in Belarus, South Africa
- Volunteers
- 240 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Lung Tuberculosis, MDR TB
Tuberculosis Research of INA-RESPOND On Drug Resistance
This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray…
- Trial name
- TRIPOD (NCT02758236)
- Testing
- No Intervention
- Where
- 7 sites in Indonesia
- Volunteers
- 490 people
- Sponsor
- Ina-Respond
Tuberculosis, Pulmonary, Antibiotic Prophylaxis
Prevention of Tuberculosis in Prisons
The purpose of this study is to determine if the isoniazid is effective in the prevention of tuberculosis in a prison population, exposed to the high endemicity of the disease.
- Trial name
- NCT03028129
- Testing
- Isoniazid 900 milligrams
- Where
- Brazil
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Lung Diseases, Tuberculosis
Indigenous Outreach Among Injection Drug Users to Treat and Control TB
The Community Outreach Intervention Project (COIP) implemented and evaluated a TB intervention with injection drug users (IDUs) in two Chicago Neighborhoods, guided by the indigenous outreach leadership model that had been used…
- Trial name
- NCT00005741
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberculosis
Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
The purpose of this study is: To evaluate the safety and tolerability of orally administered OPC-67683 when administered two times daily to MDR tuberculosis (TB) participants refractory to treatment with an optimized background…
- Trial name
- NCT01131351
- Testing
- Delamanid, Optimized Background Regimen (OBR)
- Where
- 3 sites in Latvia, Lithuania
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects
This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a longitudinal study of pulmonary TB suspects who are undergoing sputum evaluation for pulmonary TB.
- Trial name
- NCT01587469
- Where
- United States
- Volunteers
- 992 people
- Sponsor
- Cepheid